نتایج جستجو برای: cytarabine

تعداد نتایج: 4434  

Journal: :American Journal of Clinical Pathology 2018

2016
Claudia M. Kowolik Min Lin Jun Xie Larry E. Overman David A. Horne

Acute myeloid leukemia (AML) is an aggressive malignancy characterized by heterogeneous genetic and epigenetic changes in hematopoietic progenitors that lead to abnormal self-renewal and proliferation. Despite high initial remission rates, prognosis remains poor for most AML patients, especially for those harboring internal tandem duplication (ITD) mutations in the fms-related tyrosine kinase-3...

2018
Xiao-Ping Xi Yu-Jin Zong Yan-Hong Ji Bing Wang Hua-Sheng Liu

It has been shown that low frequency ultrasound in the presence of microbubble can effectively open the blood brain barrier (BBB) to allow the drugs to be delivered into the brain with an increased concentration. We aim to apply this method to increase the efficacy of Cytarabine (Ara-c) to treat central nervous system leukemia (CNSL). In the present study, we validated this ultrasound contrast ...

Journal: :Haematologica 2010
Wendy Deenik Jeroen J W M Janssen Bronno van der Holt Gregor E G Verhoef Willem M Smit Marie José Kersten Simon M G J Daenen Leo F Verdonck Augustin Ferrant Anton V M B Schattenberg Pieter Sonneveld Marinus van Marwijk Kooy Shulamit Wittebol Roelof Willemze Pierre W Wijermans H Berna Beverloo Bob Löwenberg Peter J M Valk Gert J Ossenkoppele Jan J Cornelissen

BACKGROUND In order to improve the molecular response rate and prevent resistance to treatment, combination therapy with different dosages of imatinib and cytarabine was studied in newly diagnosed patients with chronic myeloid leukemia in the HOVON-51 study. DESIGN AND METHODS Having reported feasibility previously, we hereby report the efficacy of escalated imatinib (200 mg, 400 mg, 600 mg o...

Journal: :The hematology journal : the official journal of the European Haematology Association 2004
Thomas Prébet Sophie Ducastelle Stephan Debotton Aspasia Stamatoullas Eric Deconinck Christophe Fruchart Nicole Gratecos Norbert Ifrah François Dreyfus Pierre Fenaux Eric Wattel

Since leukemic cells primed by exposure to fludarabine exhibit enhanced accumulation of cytarabine triphosphate (the cytotoxic nucleotide of cytarabine), especially with continuous cytarabine (AraC) infusion, a phase II trial was designed to explore the feasibility and efficacy of a combination chemotherapy associating fludarabine, mitoxantrone (MXN), and high-dose cytarabine (continuous infusi...

2010
K. Brandt K. Schäkel F. Stölzel J. Janschek G. Ehninger M. Schaich

Cytarabine is an effective drug in the treatment of haematological malignancies. The therapy is associated with various complications. Frequencies of dermatological side-effects range from 2-72% and occur most commonly after high-dose regimens. Although most cutaneous reactions are mild and resolve spontaneously within several days, they may result in an increased risk of infection and alterati...

2014
Sarah M. Leonard Tracey Perry Ciarán B. Woodman Pamela Kearns

The current interest in epigenetic priming is underpinned by the belief that remodelling of the epigenetic landscape will sensitise tumours to subsequent therapy. In this pre-clinical study, paediatric AML cells expanded in culture and primary AML xenografts were treated with decitabine, a DNA demethylating agent, and cytarabine, a frontline cytotoxic agent used in the treatment of AML, either ...

Journal: :Blood 2005
Kenneth F Bradstock Jane P Matthews Raymond M Lowenthal Heather Baxter John Catalano Timothy Brighton Devinder Gill Paul Eliadis Douglas Joshua Paul Cannell Anthony P Schwarer Simon Durrant Anne Gillett Jerry Koutts Kerry Taylor John Bashford Christopher Arthur Arno Enno Lindsay Dunlop Jeff Szer Michael Leahy Surender Juneja Graham A R Young

The value of administering sequential courses of chemotherapy containing high-dose cytarabine in both induction and consolidation therapy for acute myeloid leukemia (AML) has not been assessed in a prospective randomized trial. Two hundred ninety-two AML patients aged 15 to 60 years were enrolled in the Australasian Leukaemia and Lymphoma Group (ALLG) AML trial number 7 (M7) protocol to evaluat...

Journal: :American journal of translational research 2017
Zhaoyun Liu Jin Chen Honglei Wang Kai Ding Yanqi Li Anya de Silva Varun Sehgal Jonathan Lvan Burbano Radhika Sundararaj Janani Gamage Victor Audu Rong Fu

Chidamide is a newly designed and synthesized histone deacetylase (HDAC) inhibitor that selectively inhibits HDAC 1, 2, 3, and 10. Our previous study demonstrated that chidamide induces G0/G1 arrest and apoptosis in myelodysplastic syndromes (MDS). Low-dose chemotherapy is effective in treating higher risk MDS patients, and here, we sought to determine whether the combination of chidamide with ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید